Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lifted its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 1.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 489,162 shares of the company’s stock after purchasing an additional 7,661 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Amneal Pharmaceuticals were worth $4,070,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Rothschild Investment LLC purchased a new stake in Amneal Pharmaceuticals in the second quarter valued at about $26,000. Gladius Capital Management LP purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at approximately $37,000. DekaBank Deutsche Girozentrale acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter worth approximately $42,000. nVerses Capital LLC acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter worth approximately $62,000. Finally, Bayesian Capital Management LP purchased a new stake in Amneal Pharmaceuticals during the 1st quarter worth approximately $65,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AMRX shares. StockNews.com upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 11th. Piper Sandler boosted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Barclays increased their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Truist Financial lifted their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $10.00.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the transaction, the senior vice president now owns 13,665 shares in the company, valued at approximately $117,655.65. This represents a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 26.56% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $8.39 on Friday. The stock has a market capitalization of $2.60 billion, a price-to-earnings ratio of -12.34 and a beta of 1.17. The firm’s 50 day simple moving average is $8.57 and its 200-day simple moving average is $7.72. Amneal Pharmaceuticals, Inc. has a 12 month low of $4.16 and a 12 month high of $9.48.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.